35773-92-3

Upstream product

• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 75-36-5 acetyl chloride 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 99-10-5 3,5-Dihydroxybenzoic acid 

Downstream Products

• 1360866-40-5 (1S,5'S)-5'-(tert-butyldiphenylsilyloxy)-6'-((tert-butyldiphenylsilyloxy)methyl)-5,7-dimethoxy-3',4',5',6'-tetrahydro-3H-spiro-[isobenzofuran-1,2'-pyran]-3',4'-diol 
• 1360866-41-6 (1S,5'S)-5'-(tert-butyldiphenylsilyloxy)-6'-((tert-butyldiphenylsilyloxy)methyl)-5,7-dimethoxy-3',4',5',6'-tetrahydro-3H-spiro-[isobenzofuran-1,2'-pyran]-3',4'-diol 
• 1360866-37-0 1-(2-((tert-butyldimethylsilyloxy)methyl)-4,6-dimethoxyphenyl)-2-hydroxyethanone 
• 1360866-36-9 1-(2-((tert-butyldimethylsilyloxy)methyl)-4,6-dimethoxyphenyl)ethanone 
• 1360866-35-8 1-(2-((tert-butyldimethylsilyloxy)methyl)-4,6-dimethoxyphenyl)ethanol 
• 1360866-38-1 C₂₀H₃₆O₄Si₂ 
• 1360866-34-7 1-(2-(hydroxymethyl)-4,6-dimethoxyphenyl)ethanol 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS AND THEIR USE

The invention relates to compounds that have antiviral activity, particularly 4-oxochromane derivatives that have antiviral activity against viruses of the Family Flaviviridae. Methods of treating viruses with the 4-oxochromane compounds, particularly viruses of the Family Flaviviridae, are also described.

Molecular modeling studies and: In vitro screening of dihydrorugosaflavonoid and its derivatives against Mycobacterium tuberculosis

Novel drug regimens against tuberculosis (TB) are urgently needed and may be developed by targeting essential enzymes of Mtb that sustain the pathogenicity of tuberculosis. In the present investigation, series of compounds (5a-f and 6a-f) based on a naturally occurring rugosaflavonoid moiety were evaluated by in silico molecular modeling studies against β-ketoacyl-ACP reductase (MabA) (PDB ID: IUZN) and pantothenate kinase (PanK) (PDB ID: 3AF3). Compounds 5a, 5c, 5d, and 6c, which had docking scores of -8.29, -8.36, -8.17 and -7.39 kcal mol-1, respectively, displayed interactions with MabA that were better than those of isoniazid (-6.81 kcal mol-1). Similarly, compounds 5a, 5c, 5d, and 6c, which had docking scores of -7.55, -7.64, -7.40 and -6.7 kcal mol-1, respectively, displayed interactions with PanK that were comparable to those of isoniazid (-7.64 kcal mol-1). Because of their docking scores, these compounds were screened in vitro against Mycobacterium tuberculosis H37Ra (Mtb) using an XRMA protocol. Among the screened compounds, the dihydrorugosaflavonoid derivatives 5a, 5c, and 5d had IC50 values of 12.93, 8.43 and 11.3 μg mL-1, respectively, and exhibited better inhibitory activity than the parent rugosaflavonoid derivatives. The rugosaflavonoid derivative 6c had an IC50 value of 17.57 μg mL-1. The synthesized compounds also displayed inhibitory activity against the Gram-positive bacteria Bacillus subtilis and Staphylococcus aureus. The present study will be helpful for the further development of these molecules into antitubercular lead candidates.

First synthesis of rugosaflavonoid and its derivatives and their activity against breast cancer

Rugosaflavonoid, is a secondary metabolite isolated from the plant Rosa rugosa was synthesized in five simple steps from commercially available 3,5-dihydroxy benzoic acid involving domino aldol-Michael-oxidation reaction. This is the first report of the synthesis of rugosaflavonoid (6a). A series of its derivatives were also synthesized, characterized and evaluated for the cytotoxicity against the breast cancer MCF-7 and normal NIH3T3 cell lines. The synthetic derivatives of rugosaflavonoid showed comparable activity in both the cell lines and compounds 6d, 6e and 6f, which were found to be cytotoxic towards MCF-7 cell lines but nontoxic to NIH3T3 cell lines at 5 μM concentration. In an attempt to explore the mode of action of the best active compounds, docking on the ATP binding site of EGFR (1M17) was performed considering that EGFR over-expressed in most of the tumors. The docking score (Gscore) of 6f and standard quercetin was found to be -8.608 and -8.310 respectively.

Rational design of inhibitors of VirA-VirG two-component signal transduction

VirA-VirG two-component system regulates the vir (virulence) operon in response to specific host factors (xenognosins) in the plant pathogen Agrobacterium tumefaciens. Using whole cell assays, stable inhibitors inspired by the labile natural benzoxazinone inhibitor HDMBOA are developed. It is found that aromatic aldehydes represent a minimal structural unit for activity. In particular, 3-hydroxy-4,6-dimethoxy-3H-isobenzofuran-1-one (HDI) was found to have the highest activity, making it the most potent developed inhibitor of virulence gene expression in Agrobacterium.

Enantiomerically homogeneous intermediates toward the synthesis of descarbamoylcalicheamicinone

Enzymatically mediated kinetic resolution of racemic 12 with lipase PS-30 provides a practical route to the aglycones of descarbamoylcalicheamicin.